This is the application area with the deepest preclinical history, and it is also where oral administration has a particularly direct anatomical rationale - the compound passes through the GI tract it was originally studied in relation to
Human data lacking To date, most (if not all) data is preclinical (rodents, cell culture)
Medical supervision also means that your treatment is personalized from day one

Researched applications The published preclinical literature documents the effects of BPC-157 in the following areas (mostly in animal models): Tendon and ligament healing , Achilles tendon, medial collateral ligament (MCL, the ligament on the inner side of the knee), tendinopathy models Muscle injuries , quadriceps (front thigh), gastrocnemius (calf muscle), transections and contusions Bone and joint healing , osteoarthritis models, fracture healing, periodontal tissues (around the teeth) Gastrointestinal diseases , gastric lesions caused by alcohol or NSAIDs (ibuprofen, diclofenac), colitis, IBD models (Crohns disease), fistulas Hepatoprotection , protection of the liver against toxic damage (paracetamol overdose, CCl, alcohol) Vascular healing , endothelial dysfunction, thromboses, healing of vascular anastomoses after surgery, thrombocytopenia (low platelet count) Skin wounds , acute as well as diabetic wounds, burns Nerve regeneration , peripheral (sciatic nerve crush) as well as central (cerebral ischemia models, i.e
